Official Title

Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Intervention/Treatment

    somatropin ...
  • Study Participants

    15
Fifteen to twenty percent of adults who suffer a traumatic brain injury (TBI) that requires hospitalization and rehabilitation have been found to have growth hormone (GH) deficiency by GH stimulation testing. Moreover, abnormalities have also been established for the cortisol and thyroid axis. The hypothesis of this proposal is that hormone replacement in TBI patients with documented abnormalities in the GH, thyroid, or cortisol axis will improve muscle function, body composition, aerobic capacity (GH) and tests of neuropsychologic function (GH, thyroid, cortisol).
This protocol is designed to screen and detect evidence of pituitary hormone deficiency in adults following traumatic brain injury. Growth hormone deficiency will be replaced for a period of one year. Subject will not be screened until at least one year following brain injury to allow for natural recovery of hormone function.
Study Started
Nov 30
2003
Primary Completion
Oct 31
2015
Study Completion
Oct 31
2015
Results Posted
May 15
2018
Last Update
Jun 29
2018

Drug Recombinant human growth hormone

200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)

  • Other names: Genotropin, Somatropin, hGH

Human Growth Hormone Experimental

recombinant human growth hormone (rhGH) self administered daily for one year

Criteria

Inclusion Criteria:

Patients aged 21 and older.
Documented moderate to severe traumatic brain injury at least one year post injury.

Exclusion Criteria:

The only absolute exclusionary medication will be an anticoagulant (Coumadin) because of the risk of bleeding during the possible muscle biopsy procedure and daily injections of rhGH in the GH arm of the study.
Any subject with a history of hepatitis or a 3-fold elevation of liver function tests (Alk phos, alanine aminotransferase (ALT), aspartate aminotransferase (AST)). We are uncertain of the effects of hormone replacement such as rhGH on the liver, so we will exclude any subjects with hepatitis. This exclusion applies only to subjects who would be enrolled in the GH arm of the study.
Subjects who are deficient in cortisol or thyroid at screening will be excluded until hormone abnormalities have been corrected.
Subjects with chronic pain who are being managed with narcotics will be excluded as the effects of central nervous system depressants may interfere with study test results.

Summary

Human Growth Hormone

All Events

Event Type Organ System Event Term

Maximum Oxygen Uptake After One Year of Human Growth Hormone Replacement Therapy.

Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Human Growth Hormone

32.1
mL/kg/min (Mean)
Standard Deviation: 7.4

Minute Ventilation at Baseline.

Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Human Growth Hormone

90.4
L/minute (Mean)
Standard Deviation: 24.2

Minute Ventilation After One Year of Human Growth Hormone Replacement Therapy.

Minute ventilation was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Human Growth Hormone

102.4
L/minute (Mean)
Standard Deviation: 23.1

Respiratory Exchange Ratio at Baseline.

Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Human Growth Hormone

1.27
ratio of CO2/O2 (Mean)
Standard Deviation: 0.12

Respiratory Exchange Ratio After One Year of Human Growth Hormone Replacement Therapy.

Respiratory exchange ratio was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Human Growth Hormone

1.27
ratio of CO2/O2 (Mean)
Standard Deviation: 0.10

Oxygen Pulse at Baseline.

Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.

Human Growth Hormone

15.2
mL/beat (Mean)
Standard Deviation: 4.1

Oxygen Pulse After One Year of Human Growth Hormone Replacement Therapy.

Oxygen Pulse was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart. Oxygen pulse is calculated by dividing VO2 consumed (mL/min) by heart rate (beats/min) yielding mL/beat. This provides an estimate of cardiac stroke volume.

Human Growth Hormone

16.4
mL/beat (Mean)
Standard Deviation: 4.2

Maximum Oxygen Uptake at Baseline.

Maximum Oxygen Uptake was measured during cardiorespiratory testing using a modified Balke protocol with expired gases collected and analyzed by an automated metabolic cart.

Human Growth Hormone

29.0
mL/kg/min (Mean)
Standard Deviation: 7.2

Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy.

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Human Growth Hormone

11.2
scores on a scale (Mean)
Standard Deviation: 2.6

Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall at Baseline

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Human Growth Hormone

18.7
scores on a scale (Mean)
Standard Deviation: 5.7

Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. Total recall is a measure of the subjects memory immediately after viewing the stimulus page. Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Human Growth Hormone

22.7
scores on a scale (Mean)
Standard Deviation: 5.1

Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall at Baseline

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Human Growth Hormone

7.2
scores on a scale (Mean)
Standard Deviation: 2.9

Neuropsychological Function as Measured by Brief Visuospatial Memory Test-R With Delayed Recall After 1 Year of Human Growth Hormone Replacement Therapy

The Brief Visuospatial Memory Test is measure of visual memory. The subject views a stimulus page with 6 shapes on it for 10 seconds. The subjects are then asked to draw as many figures as they remember in the correct locations as possible. The delayed recall is a measure of the subjects memory after a 25 minutes delay. The participants are asked to freely recall and again draw the six figures.Data is reported as raw scores. Scores range from 0 (lowest) to 36 (highest). A higher score indicates a better outcome.

Human Growth Hormone

9.1
scores on a scale (Mean)
Standard Deviation: 2.2

Neuropsychological Function as Measured by Digit Span Total at Baseline

Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.

Human Growth Hormone

16.0
scores on a scale (Mean)
Standard Deviation: 4.5

Neuropsychological Function as Measured by Digit Span Total After One Year of Human Growth Hormone Replacement Therapy.

Digit Span; Wechsler Memory Scale III (WMS III). Digits Forward is a test of digit span (range = 3 to 9 digits) consisting of seven items (each with 2 trials). Digits Backward is a test of digit span (range = 3 to 9 digits); however the participant must provide the presented sequence in reverse order. The test consists of seven items (each with 2 trials). Total score is calculated by adding the scores from forward and backward. Data is reported as raw scores. Score ranges are 0 (lowest) to 32 (highest). A higher score indicates a better outcome.

Human Growth Hormone

17.0
scores on a scale (Mean)
Standard Deviation: 3.9

Neuropsychological Function as Measured by Processing Speed Index at Baseline

Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output. This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work "NO". Total correct responses for both task within 120 seconds are recorded. Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.

Human Growth Hormone

102.3
scores on a scale (Mean)
Standard Deviation: 14.9

Neuropsychological Function as Measured by Processing Speed Index After One Year of Human Growth Hormone Replacement Therapy.

Processing Speed Index is a subcategory of the Wechsler Adult Intelligence Scale III (WAIS-III). Processing speed refers to the speed of cognitive processes and response output. This index is comprised of performances on two separate tests of visuomotor speed of information processing ability. On one test (Coding) participants refer to a key on top of a page to translate non-verbal symbols to an alpha-numeric digit. The participants then fill in boxes with the correct symbol assigned to a particular number. On the other test (Symbol Search) participants are asked to visually scan and mark items that are identical to one of two targets. If neither target is shown in the array the participant must mark out the work "NO". Total correct responses for both task within 120 seconds are recorded. Ranges are 0 (lowest) to 150 (highest) with 100 being the normal average. A higher score indicates a better outcome.

Human Growth Hormone

106.6
scores on a scale (Mean)
Standard Deviation: 15.0

Neuropsychological Function as Measured by Letter Fluency at Baseline

Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.

Human Growth Hormone

38.5
scores on a scale (Mean)
Standard Deviation: 14.5

Neuropsychological Function as Measured by Letter Fluency After One Year of Human Growth Hormone Replacement Therapy

Letter Fluency is a condition measured as part of the subcategory, Verbal Fluency, in the Delis-Kaplan Executive Function System (D-KEFS). Subjects are asked to name as many words as they can starting with a specified letter for 60 seconds. The words can not be names, places, numbers or grammatical variants of previous answers. Repeated answers are not scored as a correct response. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials and a Letter Fluency Score is given. A higher score is considered better. There is no set range as the score depends on how many correct words the subject relays in the given time period.

Human Growth Hormone

35.4
scores on a scale (Mean)
Standard Deviation: 13.0

Depression as Measured by the Beck Depression Inventory at Baseline.

Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.

Human Growth Hormone

13.8
scores on a scale (Mean)
Standard Deviation: 9.7

Depression as Measured by Beck Depression Inventory After One Year of Human Growth Hormone Replacement Therapy.

Beck Depression Inventory (BDI-II) is used to measure the severity of depression symptoms. The BDI-II contains 21 questions, each answer being scored on a scale value of 0 to 3. Higher total scores indicate more severe depressive symptoms. The standardized cutoffs are: 0-13: minimal depression; 14-19: mild; depression; 20-28: moderate depression; 29-63: severe depression.

Human Growth Hormone

6.2
scores on a scale (Mean)
Standard Deviation: 6.9

Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.

Maximum torque production during isometric contraction of the knee extensor muscles.

Human Growth Hormone

206.0
Newton-Meters (Mean)
Standard Deviation: 32.41

Muscle Function in Male Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.

Maximum torque production during isometric contraction of the knee extensor muscles.

Human Growth Hormone

209.6
Newton-Meters (Mean)
Standard Deviation: 37.65

Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline.

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Human Growth Hormone

175.2
Newton-Meters (Mean)
Standard Deviation: 36.61

Muscle Function in Male Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Human Growth Hormone

182.6
Newton-Meters (Mean)
Standard Deviation: 45.29

Muscle Fatigue as Measured by Biodex Pro 4 at Baseline.

Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.

Human Growth Hormone

35.1
Percent of Maximum Torque (Mean)
Standard Deviation: 6.30

Muscle Fatigue as Measured by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy.

Muscle fatigue is measured using repetitive isokinetic contractions of the knee extensors at 90 degrees per second. Each subject was asked to produce 40 contractions at full force. Data is presented as % of maximum torque at the 40th contraction in the fatigue protocol.

Human Growth Hormone

36.9
Percent of Maximum Torque (Mean)
Standard Deviation: 9.89

Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.

Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.

Human Growth Hormone

96.04
kilograms (Mean)
Standard Deviation: 18.38

Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.

Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Human Growth Hormone

96.55
kilograms (Mean)
Standard Deviation: 19.67

Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Human Growth Hormone

61.68
kilograms (Mean)
Standard Deviation: 7.55

Lean Body Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Human Growth Hormone

63.7
kilograms (Mean)
Standard Deviation: 8.14

Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.

Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.

Human Growth Hormone

31.19
kilograms (Mean)
Standard Deviation: 13.75

Fat Free Mass in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.

Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.

Human Growth Hormone

29.67
kilogram (Mean)
Standard Deviation: 14.30

Percent Body Fat as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Human Growth Hormone

32.47
percent of body fat (Mean)
Standard Deviation: 8.47

Percent Body Fat in Male Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Human Growth Hormone

30.5
percent of body fat (Mean)
Standard Deviation: 9.40

Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 at Baseline.

Maximum torque production during isometric contraction of the knee extensor muscles.

Human Growth Hormone

131.5
Newton-Meters (Mean)
Standard Deviation: 26.38

Muscle Function in Female Subjects Measured Using Maximum Isometric Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy

Maximum torque production during isometric contraction of the knee extensor muscles.

Human Growth Hormone

130.7
Newton-Meters (Mean)
Standard Deviation: 34.77

Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 at Baseline

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Human Growth Hormone

103.9
Newton-Meters (Mean)
Standard Deviation: 12.56

Muscle Function in Female Subjects Measured Using Maximum Isokinetic Leg Extension by Biodex Pro 4 After One Year of Human Growth Hormone Replacement Therapy

Maximum torque production during maximal isokinetic contractions at 90 degrees per second.

Human Growth Hormone

99.6
Newton-Meters (Mean)
Standard Deviation: 17.58

Perceptual Fatigability as Measured by a Fatigue Rating Scale at Baseline.

Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.

Human Growth Hormone

3.78
units on a scale (Mean)
Standard Deviation: 1.75

Perceptual Fatigability as Measured by a Fatigue Rating Scale After One Year of Human Growth Hormone Therapy.

Perceptual fatigue was measured before and directly after performing the muscle fatigue exercise protocol (40 continuous maximal force isokinetic knee extensions at 90 degress per second). Subjects were asked to rate their fatigue on a scale of 0-10 with 0 being no fatigue at all and 10 being extreme fatigue. Data is presented as change in fatigue rating induced by exercise testing.

Human Growth Hormone

3.17
units on a scale (Mean)
Standard Deviation: 1.54

Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.

Human Growth Hormone

75.64
kilograms (Mean)
Standard Deviation: 10.80

Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.

Fat free mass is calculated from whole body scan measured using a GE Lunar iDEXA.

Human Growth Hormone

29.31
kilograms (Mean)
Standard Deviation: 9.86

Fat Free Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy

Fat free mass is calculated from whole body scan measured on a GE Lunar iDEXA.

Human Growth Hormone

29.15
kilograms (Mean)
Standard Deviation: 8.74

Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Human Growth Hormone

38.92
percent of body fat (Mean)
Standard Deviation: 8.17

Fatigue as Measured Using Fatigue Severity Scale at Baseline.

Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.

Human Growth Hormone

44.3
scores on a scale (Mean)
Standard Deviation: 13.5

Percent Body Fat in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.

Percent body fat is calculated from a whole body scan measured on a GE Lunar iDEXA.

Human Growth Hormone

38.74
percent of body fat (Mean)
Standard Deviation: 6.84

Fatigue Measured Using the Fatigue Severity Scale After One Year of Human Growth Hormone Therapy.

Fatigue Severity Scale (FSS) is a measure of fatigue and how that fatigue interferes with life. It is a 9-item scale, with a range from 9 to 63, with a higher number indicating greater severity.

Human Growth Hormone

34.0
scores on a scale (Mean)
Standard Deviation: 12.5

Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy

Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Human Growth Hormone

76.54
kilograms (Mean)
Standard Deviation: 10.57

Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA.

Human Growth Hormone

43.84
kilograms (Mean)
Standard Deviation: 1.42

Lean Body Mass in Female Subjects as Measured by Dual Energy X-Ray Absorptiometry (DEXA) After One Year of Human Growth Hormone Replacement Therapy.

Lean Body mass was calculated from whole body scan taken using a GE Lunar iDEXA

Human Growth Hormone

44.92
kilograms (Mean)
Standard Deviation: 3.47

Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall at Baseline.

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Human Growth Hormone

45.7
scores on a scale (Mean)
Standard Deviation: 10.8

Neuropsychological Function as Measured by California Verbal Learning Test-II With Total Recall After 1 Year of Human Growth Hormone Replacement Therapy.

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Total recall is a sum of all word list items correctly recalled immediately on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Human Growth Hormone

51.0
scores on a scale (Mean)
Standard Deviation: 9.4

Neuropsychological Function as Measured by California Verbal Learning Test-II With Delayed Recall at Baseline.

The California Verbal Learning Test II (CVLT-II) is a comprehensive assessment of verbal learning and memory. Subjects are read a list of 16 words. Delayed recall is a sum of all word list items correctly recalled after a 25 minute delay on learning trials 1 through 5. Data is reported as raw scores. Score range is 0 (lowest) to 80 (highest). A higher score indicates a better outcome.

Human Growth Hormone

9.9
scores on a scale (Mean)
Standard Deviation: 3.8

Age at time of injury

34.3
years (Mean)
Standard Deviation: 15.7

Age, Continuous

45.5
years (Mean)
Standard Deviation: 11.2

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Human Growth Hormone